Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2009-03-13
2011-11-29
Martinell, James (Department: 1634)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S006120, C435S007100
Reexamination Certificate
active
08067178
ABSTRACT:
The present invention relates to gene sets useful in assessing prognosis and/or predicting the response of cancer, e.g. colorectal cancer to chemotherapy. In addition, the invention relates to a clinically validated cancer test, e.g. colorectal test, for assessment of prognosis and/or prediction of patient response to chemotherapy, using expression analysis. The present invention accommodates the use of archived paraffin embedded biopsy material for assay of all markers in the relevant gene sets and therefore is compatible with the most widely available type of biopsy material.
REFERENCES:
patent: 2007/0099209 (2007-05-01), Clarke et al.
patent: 2007/0105133 (2007-05-01), Clarke et al.
patent: 2009/0258795 (2009-10-01), Cowens et al.
patent: 2010/0285980 (2010-11-01), Shak et al.
patent: 2010/0291573 (2010-11-01), Cowens et al.
patent: WO2007082099 (2007-07-01), None
patent: WO2008115419 (2008-09-01), None
Callagy et al., Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clin. Cancer Res. 2006; 12(8):2468-75.
Glinsky et al., Microarray analysis identifies a death-from=cancer signature predicting therapy failure in patients with multiple types of cancer. J. Clin. Investigation 2005; 115(6):1503-21.
Miyoshi et al., Association of centrosomal kinase STK15/BTAK mRNA expression with chromosomal instability in human breast cancers. Int. J. Cancer 2001; 92:370-3.
Modlich et al., Predictors of primary breast cancers responsiveness to preoperative Epirubicin/Cyclophosphamide-based chemotherapy: translation of microarray data into clinically useful predictive sianatures. J. Translational Medicine 2005:3:32.
Nakopoulou et al., Stromelysin-3 protein expression in invasive breast cancer: Relation to proliferation, cell survival and patients' outcome. Modern Pathology 2002:15(11):1154-61.
Nessling et al., Candidate genes in breast cancer revealed by microarray-based comparative genomic hybridization of archived tissue. Cancer Res. 2005; 65(2):439-47.
Tanaka et al., Centrosomal kinase AIK1 is overexpressed in invasive ductal carcinoma of the breast. Cancer Research 1999; 59:2041-4.
Urruticoechea et al., Proliferation marker Ki-67 in early breast cancer. J. Clin. Oncology 23:7212-20, (2005).
Valkovic et al., Correlation between vascular endothelial growth factor, angiogenesis, and tumor-associated macrophages in invasive ductal breast carcinoma. Virchows Arch. 2002:440:583-8.
Notterman Daniel et al., “Transcriptional Gene Expression Profiles of Colorectal Adenoma Adenocarcinoma and Normal Tissue Examined by Oligonucleotide Arrays”, Cancer Research, 2001, vol. 61, pp. 3124-3130.
Baker Joffre B.
Cowens Wayne
Hackett James
Langone Kim
Paik Soonmyung
Bozicevic Field & Francis LLP
Francis Carol L.
Genomic Health, Inc.
Martinell James
NSABP Foundation, Inc.
LandOfFree
Gene expression markers for prediction of patient response... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Gene expression markers for prediction of patient response..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gene expression markers for prediction of patient response... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4274627